MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
$85,112
Unit: Dollar
Positive Cash Flow Breakdown
    • Proceeds from short-term convert...
    • Accretion of original issuance c...
    • Accrued payroll and payroll taxe...
    • Others
Negative Cash Flow Breakdown
    • Net loss
Cash Flow
2025-09-30
2025-06-30
Net loss
-578,503
-2,119,751
Depreciation expense
0
1,363
Stock based compensation
50,000
100,000
Accretion of debt discount
-70,211
-69,879
Accretion of original issuance costs
119,739
175,370
Modification of warrants
0
17,505
Inducement of preferred shares
0
845,901
Settlement of lease
0
5,798
Other current assets
-1,300
-7,697
Other assets
0
-20,711
Accounts payable
43,758
121,462
Accrued payroll and payroll taxes
93,645
317,113
Other current liabilities
524
1,666
Net cash used in operating activities
-199,326
-446,882
Advance from shareholder
-
0
Repayments of advance from shareholder
-
0
Proceeds from short-term convertible notes
281,438
425,197
Proceeds from short-term promissory notes
3,000
10,000
Net cash provided by financing activities
284,438
435,197
Net increase in cash
85,112
-11,685
Cash and cash equivalents at beginning of period
12,144
-
Cash and cash equivalents at end of period
85,571
-
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from short-termconvertible notes$281,438 Proceeds from short-termpromissory notes$3,000 Net cash provided byfinancing activities$284,438 Net increase in cash$85,112 Canceled cashflow$199,326 Accretion of originalissuance costs$119,739 Accrued payroll andpayroll taxes$93,645 Accretion of debt discount-$70,211 Stock basedcompensation$50,000 Accounts payable$43,758 Other current assets-$1,300 Other currentliabilities$524 Net cash used inoperating activities-$199,326 Canceled cashflow$379,177 Net loss-$578,503

Sigyn Therapeutics, Inc. (SIGY)

Sigyn Therapeutics, Inc. (SIGY)